Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Patient-reported outcomes after personalised dose-escalation for stage II-III non-small-cell lung cancer patients: Results from the randomised ARTFORCE PET-Boost trial.
Cooke SA, Belderbos JSA, Reymen B, Lambrecht M, Fredberg Persson G, Faivre-Finn C, Dieleman EMT, van Diessen JNA, Sonke JJ, de Ruysscher D. Cooke SA, et al. Among authors: van diessen jna. Radiother Oncol. 2024 Jul;196:110312. doi: 10.1016/j.radonc.2024.110312. Epub 2024 Apr 24. Radiother Oncol. 2024. PMID: 38663582 Clinical Trial.
Long-term follow-up of patients with locally advanced non-small cell lung cancer receiving concurrent hypofractionated chemoradiotherapy with or without cetuximab.
Walraven I, van den Heuvel M, van Diessen J, Schaake E, Uyterlinde W, Aerts J, Koppe F, Codrington H, Kunst P, Dieleman E, van de Vaart P, Verheij M, Belderbos J. Walraven I, et al. Radiother Oncol. 2016 Mar;118(3):442-6. doi: 10.1016/j.radonc.2016.02.011. Epub 2016 Feb 15. Radiother Oncol. 2016. PMID: 26900091 Clinical Trial.
The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial).
van Diessen J, De Ruysscher D, Sonke JJ, Damen E, Sikorska K, Reymen B, van Elmpt W, Westman G, Fredberg Persson G, Dieleman E, Bjorkestrand H, Faivre-Finn C, Belderbos J. van Diessen J, et al. Radiother Oncol. 2019 Feb;131:166-173. doi: 10.1016/j.radonc.2018.09.019. Epub 2018 Oct 13. Radiother Oncol. 2019. PMID: 30327236 Clinical Trial.
Local and regional treatment response by 18FDG-PET-CT-scans 4 weeks after concurrent hypofractionated chemoradiotherapy in locally advanced NSCLC.
van Diessen JNA, La Fontaine M, van den Heuvel MM, van Werkhoven E, Walraven I, Vogel WV, Belderbos JSA, Sonke JJ. van Diessen JNA, et al. Among authors: van werkhoven e, van den heuvel mm. Radiother Oncol. 2020 Feb;143:30-36. doi: 10.1016/j.radonc.2019.10.008. Epub 2019 Nov 22. Radiother Oncol. 2020. PMID: 31767474 Clinical Trial.
In response to Park, et al.
van Diessen JNA, Kwint MH, Sonke JJ, Belderbos JSA. van Diessen JNA, et al. Radiother Oncol. 2020 Jun;147:245-246. doi: 10.1016/j.radonc.2020.03.036. Epub 2020 Apr 4. Radiother Oncol. 2020. PMID: 32312603 No abstract available.
18F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): Results from a randomised clinical trial.
Cooke SA, de Ruysscher D, Reymen B, Lambrecht M, Fredberg Persson G, Faivre-Finn C, Dieleman EMT, Lewensohn R, van Diessen JNA, Sikorska K, Lalezari F, Vogel W, van Elmpt W, Damen EMF, Sonke JJ, Belderbos JSA. Cooke SA, et al. Among authors: van diessen jna. Radiother Oncol. 2023 Apr;181:109492. doi: 10.1016/j.radonc.2023.109492. Epub 2023 Jan 24. Radiother Oncol. 2023. PMID: 36706958 Clinical Trial.
25 results